FDA approves Lumvoa for thyroid eye disease

morningstar.com·Jun 27, 2026 · 2 mesi fa

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

endpoints.news·Jun 27, 2026 · 2 mesi fa

FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza

benzinga.com·Jun 29, 2026 · 1 mese fa

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid

medpagetoday.com·Jun 29, 2026 · 1 mese fa

New Drug Approved for Thyroid Eye Disease

biopharmadive.com·Jun 30, 2026 · 1 mese fa

Viridian may have edge over Amgen in eye drug showdown, analysts argue

fiercepharma.com·Jun 29, 2026 · 1 mese fa

Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa

morningstar.com·Jun 30, 2026 · 1 mese fa

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

endpoints.news·Jul 2, 2026 · 1 mese fa

Otsuka reports long-term kidney data key to Voyxact's bid for full approval